CCND1 and endometrium adenocarcinoma: These findings suggest that a subset endometrial adenocarcinomas possesses a unique spectrum of somatic CCND1 mutations in which activating mutations occurring in the carboxy terminal domain of cyclin D1 are enriched, compared to other cancer types, thereby promoting cyclin D1 nuclear expression, gain of function and oncogenic activation.